KORSANA BIOSCIENCES, INC.
About KORSANA BIOSCIENCES, INC.
Korsana Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious central nervous system diseases, with an initial emphasis on neurodegenerative conditions such as Alzheimer's disease. Its lead program, KRSA-028, is a next-generation shuttled monoclonal antibody targeting amyloid beta. The company emerged from stealth and completed a reverse merger with Cyclerion Therapeutics to operate publicly on Nasdaq under the ticker KRSA.
- 🔗 Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases
- 🔗 Cyclerion merges with Korsana in $380M reverse merger
- 🔗 EX-99.1
- 🔗 Korsana Biosciences (KRSA) | Trefis
- 🔗 Cyclerion to Merge With Korsana, Backed by $380M | CYCN Stock News
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Completed reverse merger with Cyclerion Therapeutics to list on Nasdaq as KRSA with concurrent $380M private placement.
- Initial financing expected to fund operations and key milestones into 2029.
- Lead asset KRSA-028 targets amyloid beta for Alzheimer's with anticipated Phase 1 data in mid-2027.
- Post-transaction cash position of approximately $475 million supports multiple clinical data readouts through 2027-2028.
Ask StreetZero about KORSANA BIOSCIENCES, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account